Physician profile
Mark A Zaetta
NPI 1114901394
$1,662.18
in general payments reported to CMS, 2019-2025
17 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2021: $130 · 2022: $292 · 2023: $122 · 2024: $285 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $363.53 | 2019-2024 | Sir-Spheres Microspheres |
| Penumbra, INC. | $167.67 | 2025 | Ruby Coil |
| Glaxosmithkline, LLC. | $150.45 | 2019-2023 | Arexvy |
| Bard Peripheral Vascular, INC. | $135.92 | 2024 | Venovo |
| Novo Nordisk INC | $134.58 | 2019-2025 | Ozempic |
| Pfizer INC. | $130.84 | 2019 | |
| Medtronic, INC. | $129.62 | 2021 | |
| Trisalus Life Sciences, INC. | $111.84 | 2022 | |
| Eisai INC. | $90.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.76 | 2024 | Farxiga |
| Incyte Corporation | $53.70 | 2025 | Monjuvi, Zynyz, Jakafi |
| Edwards Lifesciences Corporation | $30.31 | 2025 | Sapien 3 Ultra Resilia |
| Vifor Pharma, INC. | $18.19 | 2019 | |
| Philips North America LLC | $17.39 | 2019 | |
| Abbott Laboratories | $14.04 | 2025 | Freestyle Libre 3 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.01 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zaetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.